World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF KIDNEY CANCER USING SIMILAR MOLECULE - LENVATINIB MESYLATE MONOHYDRATE

Dr. Syed Ahmed Hussain*, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa, Raheem Unnisa Shaik and Nazneen

ABSTRACT

Aim: This study aims to evaluate the cytotoxic effects of Lenvatinib mesylate monohydrate on kidney cancer cells using a variety of in vitro assays. Objective: The primary objective is to assess the dose-dependent inhibition of kidney cancer cell viability by Lenvatinib mesylate monohydrate and compare its activity with the control drug, Everolimus. Research: Kidney cancer cells were treated with Lenvatinib mesylate monohydrate at concentrations of 1 µM, 5 µM, and 10 µM. Cell viability was assessed using MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH Cytotoxicity assays. The results showed a significant reduction in cell viability in a dose-dependent manner, with the MTT assay indicating a drop from 86% at 1 µM to 34% at 10 µM. Similar trends were observed in the other assays, except for the LDH Cytotoxicity Assay, which showed higher cell viability at 10 µM, suggesting potential effects on cell membrane integrity or necrotic pathways. Conclusion: Lenvatinib mesylate monohydrate demonstrated potent anti-proliferative effects on kidney cancer cells. While the compound shows promise as a therapeutic agent, further research is needed to explore its mechanisms of action and confirm its efficacy at higher concentrations.

[Full Text Article]   [Download Certificate]